Back to Search
CASEY UNDERHILL, MD
MD
Emergency Medicine Physician
NPI: 1578925202IndividualAccepts Medicare
Specialties, Licenses & Credentials
Military Health Care Provider
Military Health Care Provider
Code: 171000000X
01078831A(IN)
General Practice Physician
General Practice
Code: 208D00000X
01078831A(IN)
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
01078831A(IN)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 2016
Research & Publications (20)
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
PMID 18334829·Oncology·2007
3-trial
Characterization and measurement of the plasma alpha- and beta-sex hormone-binding globulin paralogs in salmon.
PMID 18703621·Endocrinology·2009
7-preclinical
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
PMID 19363437·Am J Clin Oncol·2009
3-trial
Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?
PMID 19477634·Eur J Cancer·2009
6-review
In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulin.
PMID 18725242·Toxicol Appl Pharmacol·2009
7-preclinical
Effects of aggressive encounters on plasma corticosteroid-binding globulin and its ligands in white-crowned sparrows.
PMID 19591833·Horm Behav·2009
7-preclinical
Residues in the human corticosteroid-binding globulin reactive center loop that influence steroid binding before and after elastase cleavage.
PMID 19011238·J Biol Chem·2009
7-preclinical
Success indicators for integrating mental health interventions with community-based rehabilitation projects.
PMID 19008676·Int J Rehabil Res·2008
4-observational
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
PMID 18932253·Cancer·2008
3-trial
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
PMID 18768781·Blood·2008
3-trial
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
PMID 17653074·Br J Cancer·2007
3-trial
Barriers to improvement of mental health services in low-income and middle-income countries.
PMID 17804061·Lancet·2007
6-review
Corticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered release.
PMID 17644521·J Biol Chem·2007
7-preclinical
The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation.
PMID 17043108·Mol Cell Biol·2007
7-preclinical
Inequity in rural cancer survival in Australia is not an insurmountable problem.
PMID 17137450·Med J Aust·2006
8-other
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
PMID 16428487·Clin Cancer Res·2006
4-observational
An educational workshop program for rural practitioners to encourage best practice for delivery of systemic adjuvant therapy.
PMID 16918288·J Cancer Educ·2006
8-other
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
PMID 16061867·Clin Cancer Res·2005
3-trial
Hypoxia-induced alterations in hyaluronan and hyaluronidase.
PMID 16594159·Adv Exp Med Biol·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 380 HOSPITAL DR, SUITE 380
MACON, GA 31217 - Phone
- (478) 751-0181
Quick Facts
- NPI
- 1578925202
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile